<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T06:54:01Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/16323" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/16323</identifier><datestamp>2026-09-24T02:57:58Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Bramson, Jonathan</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Tantalo, Daniela</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Medical Sciences (Molecular Virology and Immunology Program)</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-11-06T14:57:44Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-11-06T14:57:44Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2014-11</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/16323</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/11365</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Cancer immunotherapy is emerging as a powerful tool in the treatment of cancer.  Multiple clinical trials have established that infusion of tumour-specific T cells can cause regression of advanced tumours and prevent tumour relapse. While tumour-specific T cells are typically rare, engineering methods have been developed to introduce tumour-specific receptors into T cells and engender peripheral blood T cells with the ability to kill tumour cells. These engineering successes notwithstanding, tumour cells demonstrate variable sensitivity to T cell attack. Therefore, to maximize the impact of the engineered T cells, it is necessary to develop therapeutic strategies that render tumour cells sensitive to immune attack. For my thesis research, I sought to develop a high throughput screening assay that would allow me to screen chemical libraries for agents that sensitize tumour cells to T cell attack. My ultimate goal is to define chemical agents that effectively sensitize tumour cells to T cell attack but display a better toxicity profile than existing chemotherapies. To this end, I developed a screen where resistant tumour cells were exposed to T cells engineered with chimeric antigen receptors and positive hits were defined as agents that could enhance killing of the tumour cells. My work explored both murine and human systems and I ultimately decided to use human cells for my screen.  Multiple methods for measuring tumour cell killing were evaluated, many tumour lines were screened and I optimized the conditions for generating large numbers of engineered T cells for the screen.  The net result of my thesis work is a miniaturized assay that is ready for high throughput screening.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science in Medical Sciences (MSMS)</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Immunology</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Cancer</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">High Throughput Screening</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Cancer Immunotherapy</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">T cells</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Chimeric Antigen Receptor</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">DEVELOPING A HIGH THROUGHPUT ASSAY TO INVESTIGATE CHEMICAL AGENTS WHICH SENSITIZE TUMOUR CELLS TO KILLING BY CAR ENGINEERED T CELLS</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>